ValuEngine cut shares of Mirna Therapeutics, Inc. (NASDAQ:SYBX) from a hold rating to a sell rating in a report released on Friday morning.

Mirna Therapeutics (SYBX) opened at 13.25 on Friday. The firm’s market capitalization is $215.74 million. The firm has a 50 day moving average of $12.03 and a 200 day moving average of $13.01. Mirna Therapeutics has a 12-month low of $7.84 and a 12-month high of $18.06.

COPYRIGHT VIOLATION WARNING: “Mirna Therapeutics, Inc. (SYBX) Cut to “Sell” at ValuEngine” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at

Mirna Therapeutics Company Profile

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mirna Therapeutics (NASDAQ:SYBX)

Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.